Mitoxantrone, cisplatin, and methyl-glyoxal bis-guanylhydrazone chemotherapy for refractory malignant lymphoma: a Southwest Oncology Group phase II trial.

Abstract

A phase II trial of combination chemotherapy with mitoxantrone, cisplatin, and methyl-glyoxal bix-guanylhydrazone (MGBG) was conducted in 32 patients with unfavorable histology malignant lymphoma. All patients had relapsed after only one prior chemotherapy regimen (CHOP--56%; mBACOD--28%). There were three complete and eight partial responses (overall response rate--34%) among 32 eligible patients. The median duration of remission was 6.0 months. Severe granulocytopenia was common, with 19/32 patients (63%) suffering life-threatening, and 1/32 (3%) suffering fatal, granulocytopenia. We conclude that mitoxantrone-cisplatin-MGBG has modest activity as salvage treatment in malignant lymphoma patients, but produces severe toxicity.

• Authors: B Dana, S Dahlberg, B Schnitzer, C R Kjeldsberg, S E Jones, J Carden, R Mundis, B Tranum
• Journal: Investigational new drugs (Invest New Drugs) Vol. 7 Issue 2-3 Pg. 247-50 (Jul 1989) ISSN: 0167-6997 [Print] United States
• PMID: 2793382 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Mitoxantrone
• Mitoguazone
• Cisplatin

Topics

• Adolescent
• Adult
• Aged
• Aged, 80 and over
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Cisplatin (administration & dosage, adverse effects)
• Drug Evaluation
• Female
• Humans
• Lymphoma (drug therapy)
• Male
• Middle Aged
• Mitoguazone (administration & dosage, adverse effects)
• Mitoxantrone (administration & dosage, adverse effects)